Literature DB >> 1579085

Evidence for occurrence of filovirus antibodies in humans and imported monkeys: do subclinical filovirus infections occur worldwide?

S Becker1, H Feldmann, C Will, W Slenczka.   

Abstract

In the present serological study 120 monkey sera from different species originating from the Philippines, China, Uganda and undetermined sources and several groups of human sera comprising a total of 1288 specimens from people living in Germany were examined for the presence of antibodies directed against filoviruses (Marburg virus, strain Musoke/Ebola virus, subtype Zaire, strain Mayinga/Reston virus). Sera were screened using a filovirus-specific enzyme-linked immunosorbent assay (ELISA). ELISA-positive sera were then confirmed by the indirect immunofluorescence technique, Western blot technique, and a blocking assay, and declared positive when at least one confirmation test was reactive. Altogether 43.3% of the monkey sera and 6.9% of the human sera reacted positively with at least one of the three different filovirus antigens. The blocking assays show that antibodies, detected in the sera, are directed to specific filovirus antigens and not caused by antigenic cross-reactivity with hitherto unknown agents. Data presented in this report suggest that subclinical filovirus infections may also occur in humans and in subhuman primates. They further suggest that filoviruses are not restricted to the African continent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1579085     DOI: 10.1007/bf00193395

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  33 in total

1.  Update: filovirus infections among persons with occupational exposure to nonhuman primates.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-04-27       Impact factor: 17.586

2.  Fatal human disease from vervet monkeys.

Authors:  C E Smith; D I Simpson; E T Bowen; I Zlotnik
Journal:  Lancet       Date:  1967-11-25       Impact factor: 79.321

3.  [On the etiology of an unknown human infection originating from monkeys].

Authors:  R Siegert; H L Shu; W Slenczka; D Peters; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1967-12-22       Impact factor: 0.628

4.  Antibodies in primates to the Marburg virus.

Authors:  S S Kalter; J J Ratner; R L Heberling
Journal:  Proc Soc Exp Biol Med       Date:  1969-01

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Descriptive analysis of Ebola virus proteins.

Authors:  L H Elliott; M P Kiley; J B McCormick
Journal:  Virology       Date:  1985-11       Impact factor: 3.616

7.  Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978.

Authors:  D L Heymann; J S Weisfeld; P A Webb; K M Johnson; T Cairns; H Berquist
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

8.  The nucleotide sequence of the L gene of Marburg virus, a filovirus: homologies with paramyxoviruses and rhabdoviruses.

Authors:  E Mühlberger; A Sanchez; A Randolf; C Will; M P Kiley; H D Klenk; H Feldmann
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

9.  Outbreake of Marburg virus disease in Johannesburg.

Authors:  J S Gear; G A Cassel; A J Gear; B Trappler; L Clausen; A M Meyers; M C Kew; T H Bothwell; R Sher; G B Miller; J Schneider; H J Koornhof; E D Gomperts; M Isaäcson; J H Gear
Journal:  Br Med J       Date:  1975-11-29

10.  Comparative analysis of the structural polypeptides of Ebola viruses from Sudan and Zaire.

Authors:  M J Buchmeier; R U DeFries; J B McCormick; M P Kiley
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

View more
  20 in total

1.  Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association.

Authors:  Bettina Hartlieb; Tadeusz Muziol; Winfried Weissenhorn; Stephan Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

2.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

3.  Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus.

Authors:  Verena Krähling; Dirk Becker; Cornelius Rohde; Markus Eickmann; Yonca Eroğlu; Astrid Herwig; Romy Kerber; Katharina Kowalski; Júlia Vergara-Alert; Stephan Becker
Journal:  Med Microbiol Immunol       Date:  2015-10-16       Impact factor: 3.402

4.  Suspected Exposure to Filoviruses Among People Contacting Wildlife in Southwestern Uganda.

Authors:  Tierra Smiley Evans; Leonard Tutaryebwa; Kirsten V Gilardi; Peter A Barry; Andrea Marzi; Meghan Eberhardt; Benard Ssebide; Michael R Cranfield; Obed Mugisha; Emmanuel Mugisha; Scott Kellermann; Jonna A K Mazet; Christine K Johnson
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

5.  Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo.

Authors:  Sabue Mulangu; Vivian H Alfonso; Nicole A Hoff; Reena H Doshi; Prime Mulembakani; Neville K Kisalu; Emile Okitolonda-Wemakoy; Benoit Ilunga Kebela; Hadar Marcus; Joseph Shiloach; Je-Nie Phue; Linda L Wright; Jean-Jacques Muyembe-Tamfum; Nancy J Sullivan; Anne W Rimoin
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

6.  Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak.

Authors:  Matthew L Boisen; John S Schieffelin; Augustine Goba; Darin Oottamasathien; Abigail B Jones; Jeffrey G Shaffer; Kathryn M Hastie; Jessica N Hartnett; Mambu Momoh; Mohammed Fullah; Michael Gabiki; Sidiki Safa; Michelle Zandonatti; Marnie Fusco; Zach Bornholdt; Dafna Abelson; Stephen K Gire; Kristian G Andersen; Ridhi Tariyal; Mathew Stremlau; Robert W Cross; Joan B Geisbert; Kelly R Pitts; Thomas W Geisbert; Peter Kulakoski; Russell B Wilson; Lee Henderson; Pardis C Sabeti; Donald S Grant; Robert F Garry; Erica O Saphire; Luis M Branco; Sheik Humarr Khan
Journal:  Viral Immunol       Date:  2015-02       Impact factor: 2.257

7.  Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease.

Authors:  H J Schnittler; F Mahner; D Drenckhahn; H D Klenk; H Feldmann
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Development of Prototype Filovirus Recombinant Antigen Immunoassays.

Authors:  Matt L Boisen; Darin Oottamasathien; Abigail B Jones; Molly M Millett; Diana S Nelson; Zachary A Bornholdt; Marnie L Fusco; Dafna M Abelson; Shun-Ichiro Oda; Jessica N Hartnett; Megan M Rowland; Megan L Heinrich; Marjan Akdag; Augustine Goba; Mambu Momoh; Mohammed Fullah; Francis Baimba; Michael Gbakie; Sadiki Safa; Richard Fonnie; Lansana Kanneh; Robert W Cross; Joan B Geisbert; Thomas W Geisbert; Peter C Kulakosky; Donald S Grant; Jeffery G Shaffer; John S Schieffelin; Russell B Wilson; Erica Ollmann Saphire; Luis M Branco; Robert F Garry; S Humarr Khan; Kelly R Pitts
Journal:  J Infect Dis       Date:  2015-07-30       Impact factor: 5.226

9.  Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008.

Authors:  Paul Roddy; Natasha Howard; Maria D Van Kerkhove; Julius Lutwama; Joseph Wamala; Zabulon Yoti; Robert Colebunders; Pedro Pablo Palma; Esther Sterk; Benjamin Jeffs; Michel Van Herp; Matthias Borchert
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

10.  Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus.

Authors:  Andreas Lucht; Roland Grunow; Christian Otterbein; Peggy Möller; Heinz Feldmann; Stephan Becker
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 4.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.